Henderson Morley plc's share price is also listed daily in the Financial Times and the London Evening Standard.

DOWNLOAD PROSPECTUS

Please use the link below to download the Henderson Morley share offer prospectus and application form. The prospectus requires Adobe Acrobat for viewing.

Download prospectus (466Kb)

AIM RULE 26 INFORMATION

Henderson Morley Plc was incorporated in the United Kingdom, which remains its main country of operation.

Registered in England No. 3951745

Registered Office:
Metropolitan House
2 Salisbury Road
Moseley
Birmingham B13 8JS

The number of securities currently in issue is 575,261,963 ordinary shares of 0.125p each.

The number of AIM Securities which are in issue not in public hands is 197,982,848 representing 34.42% of the issued share capital.

The identity and percentage holdings of significant shareholders:
 

Shareholder	Percentage Held
A N Knight	14.54
I S Pardoe	8.64
M P Dunne	5.18
Barclays Nominees	6.01
C Pate	0.04

There are no restrictions on the transfer of securities.

The information contained within the Investor Relations section of this website complies with the AIM Rules for Companies – February 2007.

This page was last updated on 18th April 2008.
 

LATEST REPORT AND ACCOUNTS

Please use the link below to download the Report and Accounts for for the year ended 30 April 2006. The report requires Adobe Acrobat for viewing.

Download final results (67Kb)

LATEST INTERIM REPORT

The Board of Henderson Morley plc (“Henderson Morley” or “the Company”), the AIM listed drug discovery company, announces its interim results for the six months to 31 October 2006.

HIGHLIGHTS

• Signed exclusive American, Mexican and Canadian wide licence to bring Ionic Contra Viral Therapy (ICVT) products to the market;

• Granted ICVT licence in respect of ICVT with Amistad Pharma to bring products to market through a programme of pre-clinical and clinical development;

• Successfully raised £1.65m via two placings for further commercialisation and development purposes; and

• Commenced collaboration to start field trials of a vaccine against Koi Carp Herpes virus.

Executive Chairman Andrew Knight said: “This has been a busy period for the company as we work towards the anticipated commercialisation of our patent portfolio and to develop ICVT. We will continue to seek new opportunities to grow revenues both in the near and long term by focusing on both human and animal health.

Please use the link below to download the interim results for the six months to 31 October 2004. The report requires Adobe Acrobat for viewing.

Download interim report (99Kb)

ANNUAL REPORT 2005

Please use the link below to download the Henderson Morley Annual Report for the twelve months to 30 April 2005. The report requires Adobe Acrobat for viewing.

Download annual report 2005 (510Kb)

ANNUAL REPORT 2004

Please use the link below to download the Henderson Morley Annual Report for the twelve months to 30 April 2004. The report requires Adobe Acrobat for viewing.

Download annual report 2004 (510Kb)

ANNUAL REPORT 2003

Please use the link below to download the Henderson Morley Annual Report for the twelve months to 30 April 2003. The report requires Adobe Acrobat for viewing.

Download annual report 2003 (156Kb)

ANNUAL REPORT 2002

Please use the link below to download the Henderson Morley Annual Report for the twelve months to 30 April 2002. The report requires Adobe Acrobat for viewing.

Download annual report 2002 (144Kb)